

Ravimiamet

Saara Ojala Pirkanmaan hyvinvointialue Elamanaukio 2 33520 Tampere FINLAND

21.10.2024 nr RKU-4/83

DECISION

to grant authorisation for clinical trial on the basis of Regulation (EU) No 536/2014 of the European Parliament and of the council

State Agency of Medicines has received the application from sponsor Pirkanmaan hyvinvointialue on 13.09.2024 to conduct a clinical trial under the conditions stipulated in Regulation (EU) No 536/2014 art 5 (1) and § 99^1 (1) of Estonian Medicinal Products Act (MPA).

Based on art 8 of Regulation (EU) No 536/2014, considering the aspects covered by Part I and Part II of the assessment report, on the basis of § 99^6 section 1 p 2 and (3) of Medicinal Product Act

State Agency of Medicines has decided to give the approval to conduct the clinical study protocol no ESTO2 under the following conditions:

protocol no: ESTO2 (Version 10, dated 30.08.2024)

full title of the trial: Impact of atorvastatin on prostate cancer progression after initiation of androgen deprivation therapy – lipid metabolism as a novel biomarker to predict prostate cancer progression – phase 3, double-blind randomized clinical trial FinnProstata XV. ESTO2.

sponsor of the trial: Pirkanmaan hyvinvointialue

number of subjects in Estonia: 20

principal investigators and study locations:

- Dr Andres Kotsar, Tartu University Hospital, L. Puusepa tn 1a, 50406 Tartu, Estonia

The addressee may file a challenge with State Agency of Medicines within 30 days as of the day when the addressee became or should have become aware of the decision as prescribed in Code of Administrative Procedure § 71(1). If the addressee wishes to have the decision to annulled by the administrative court, he or she may submit a complaint to the Tartu Administrative Court as prescribed in § 7(1) and § 46(1) of the Code of Administrative Court Procedure within 30 days after the date on which the decision was notified to the applicant.

(digitally signed)

Katrin Kiisk Director General